Clinical trials: Anti-Retroviral Agents
HIV Infections
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
The purpose of this study is to examine the safety, tolerability, and immune response to killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected individuals.
- Trial name
- NCT01546818
- Testing
- SAV001-H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sumagen
HIV Infections
A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults
This study is to evaluate antiviral activity, efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment naive adults.
- Trial name
- NCT04871113
- Testing
- GSK3810109A, Dolutegravir+lamivudine SOC regimen
- Where
- 24 sites in United States, Argentina and 4 more
- Volunteers
- 62 people
- Sponsor
- ViiV Healthcare
HIV Infections
Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune
The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity).
- Trial name
- NCT00979420
- Where
- 60 sites in Germany
- Sponsor
- Boehringer Ingelheim
HIV-1-infection
Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.
Phase IIa, open clinical trial, pilot, single arm and proof of concept.
- Trial name
- NCT03539224
- Testing
- Dolutegravir (DTG), Lamivudine (3TC)
- Where
- 2 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
HIV Infections
Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems
The purpose of this study is to see if children and young adults with better immune systems before starting highly active antiretroviral therapy (HAART) do better than those who have weaker immune systems before starting HAART.
- Trial name
- NCT00001097
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities
The purpose of this study is to determine the effectiveness of several anti-HIV treatment strategies in resource-poor South African communities.
- Trial name
- NCT00255840
- Testing
- Monitoring by an HIV-trained medical doctor, Monitoring by an HIV-trained primary care nurse, Efavirenz
- Volunteers
- 812 people
- Sponsor
- CIPRA SA
Anti-Infective Agents, Anti-Retroviral Agents
Safety, PK, and PD Study of IVRs Releasing TFV and LNG
This multi-center Phase I study is designed to characterize the safety, PK, and PD of TFV/LNG IVR to assess systemic and genital tract bioavailability in healthy women.
- Conditions
- Anti-Infective Agents, Anti-Retroviral Agents, Contraceptive Usage
- Trial name
- TFV/LNG IVR (NCT03279120)
- Testing
- TFV/LNG IVR
- Where
- 2 sites in United States, Dominican Republic
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- CONRAD
Human Immunodeficiency Virus
Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
The two original objectives were to determine in HIV-infected children initiating antiretroviral therapy (ART): 1. Whether clinically driven monitoring (CDM) will have a similar outcome in terms of disease progression or death as…
- Trial name
- ARROW (NCT02028676)
- Testing
- Clinically Driven Monitoring (CDM), Laboratory plus Clinical Monitoring (LCM), Arm A: ABC+3TC+NNRTI
- Where
- 4 sites in Uganda, Zimbabwe
- Volunteers
- 1,206 people
- Sponsor
- Medical Research Council
HIV
Modified Directly Observed Antiretroviral Therapy
M-DART Study is a randomized clinical trial comparing the effectiveness of a home-based modified directly observed antiretroviral (ART) treatment strategy to clinic-based standard of care in patients with HIV/AIDS in Port…
- Trial name
- M-DART (NCT01985269)
- Testing
- Home visits
- Where
- Kenya
- Volunteers
- 511 people
- Sponsor
- Moi University
Human Immunodeficiency Virus Type 1
A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study
The purpose of this study is to evaluate the long-term safety and tolerability of etravirine, administered as part of an individually optimized antiretroviral therapy (ART), in human immunodeficiency virus Type 1 (HIV-1) infected…
- Trial name
- NCT00128830
- Testing
- Etravirine (ETR), Nucleotide reverse transcriptase inhibitors (NRTIs), Protease inhibitors (PIs)
- Volunteers
- 211 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV
Some patients taking anti-HIV drugs as part of highly active antiretroviral therapy (HAART) do not show any HIV in the blood; however, some HIV will remain hidden in the body and, if the drugs are stopped, will return to the…
- Trial name
- NCT00016783
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 39 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Prevention
Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial
This is a single-arm, open-label, effectiveness study designed to evaluate the use of Tenofovir, Lamivudine, and Dolutegravir in people with newly diagnosed HIV-1 infection initiating first-line Antiretroviral Therapy with…
- Trial name
- PICASSO (NCT06485154)
- Testing
- TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir
- Where
- 3 sites in South Africa
- Volunteers
- 100 people
- Sponsor
- University of Witwatersrand, South Africa
HIV Infections
Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults
It is known successful HIV therapy depends on the patients' ability to take their medicine regularly. This study is designed to find out if an intervention designed to help patients remember to take their medication is effective.
- Trial name
- NCT00203853
- Testing
- pillbox, wristwatch
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Chicago
HIV Infections
Safety and Effectiveness of PEG-Intron in HIV-Infected Patients
The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).
- Trial name
- NCT00005012
- Testing
- Peginterferon alfa-2b
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Schering-Plough
HIV, AIDS
Motivating HIV+ Women: Risk Reduction and ART Adherence
The purpose of this study is to determine if a group motivational interviewing based intervention will increase adherence to antiretroviral medications and use of risk reduction behaviors.
- Trial name
- KHARMA (NCT00253045)
- Testing
- Motivational groups
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Emory University
Nonneoplastic Condition
Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV
RATIONALE: Vaccines made from peptides may help the body build an effective immune response. Incomplete Freund's adjuvant may stimulate the immune system in different ways and may help the vaccine work better.
- Trial name
- NCT00381875
- Testing
- E1M184V peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV Infections
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
Group A: To compare the time to confirmed virologic failure (2 consecutive plasma HIV-RNA concentrations of 500 copies/ml or more) between the treatment arms: abacavir (ABC) or placebo in combination with zidovudine (ZDV)…
- Trial name
- NCT00000885
- Testing
- Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 440 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication
The purpose of this study is to see if the amount of stem cells (cells that can develop into many kinds of cells) in the blood before anti-HIV drugs are taken can predict if the immune system will become stronger after anti-HIV…
- Trial name
- NCT00006578
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- 5 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir
When individuals who are infected with HIV are started on treatment with HIV medications, the effect of these drugs only lasts for a limited period of time, often because of development of drug resistance by the HIV virus.
- Trial name
- NCT00148785
- Testing
- Indinavir/Ritonavir/Fosamprenavir
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emory University
Autophagy, Galectins
Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.
Little is known about autophagy during HIV infection. Recently, two different teams reported important dysfunctions of autophagy in HIV-infected patients despite sustained suppressive antiretroviral therapy.
- Conditions
- Autophagy, Galectins, HIV Infections, Highly Active Antiretroviral Therapy
- Trial name
- ATGALIG-HIV (NCT04160455)
- Testing
- expression of a panel
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.